Schizophrenia has been recognized as a heterogeneous disorder characterized by diverse genetic and pathological bases. Understanding schizophrenia requires recognizing the shared pathophysiological features that exist within this variability. To address this, we aim to elucidate the common molecular pathologies of schizophrenia through studies involving genetically engineered mice with high-risk genes and patient-derived samples. Additionally, we will conduct longitudinal analyses of these shared pathological features across different disease stages to identify those present pre-onset, during the acute phase, and in the chronic phase. This approach seeks to contribute to strategies for preventing disease onset and progression.